NCT05143905 - A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7503 in Healthy Participants | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 6, 2021

Primary Completion Date

November 9, 2022

Study Completion Date

November 9, 2022

Conditions

SafetyTolerabilityPharmacokineticsHealthy Participants

Interventions

DRUG

AZD7503

Randomised participants will receive a single ascending dose of AZD7503 by SC injection (dose 1, dose 2, dose 3, dose 4, dose X and dose Y).

DRUG

Placebo

Randomised participants will receive placebo by SC injection

Trial Locations (1)

Research Site, Glendale